Stockscreener 앱 받기
6.08
1.30%
-0.08
시간 외 거래:
6.15
0.07
+1.15%
Bausch Health Companies Inc 주식(BHC)의 최신 뉴스
Idahoans may be eligible for money from generic drug settlement - KMVT
Idaho joins $17.85M settlement over alleged generic drug price-fixing - KTVB
$17.85 Million in Settlements in Ongoing Generic Drug Price-Fixing Conspiracy Cases - Big Country News
Bausch Health (BHC) Reports Next Week: Wall Street Expects Earnings Growth - Finviz
Bausch + Lomb CEO: Standing still is the new falling behind - Fortune
10 students living with GI disease to get up to $10K for school - Stock Titan
Bausch Health Cos (BHC) to Release Earnings on Wednesday - MarketBeat
AG settlements with Lannett and Bausch $17M - Oregon Business Report
Future of Ion Channel Modulators Market Growth (2026-2033) | - openPR.com
Scar Treatment Market Expected See Incredible Growth - openPR.com
Is Bausch Health (BHC) Pricing Reflect Long Term Potential After 81% Five Year Share Slump - Sahm
Migraine Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | GSK, Merck, Pfizer, Bausch Health, Amgen, Abbvie AstraZeneca, Eli Lilly and Co - Barchart.com
The Truth About Bausch Health Companies: Why Everyone Is Suddenly Paying Attention - AD HOC NEWS
Lupin’s Brazilian Subsidiary, MedQuimica Acquires Rights to Nine Brands from Bausch HealthLupin | Press Release - lupin.com
AG Drummond reaches settlement with drug companies accused of price-fixing - fox23.com
The Bull Case For Bausch Health Companies (BHC) Could Change Following Failed Xifaxan RED-C Trials Learn Why - Yahoo Finance
Wall Street Zen Upgrades Bausch Health Cos (NYSE:BHC) to "Strong-Buy" - MarketBeat
Are you eligible to receive a portion of $17 million pharmaceutical settlement? - FourStatesHomepage.com
Bausch Health (BHC) Announces Global Phase 3 RED-C Clinical Program Results - Finviz
Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (IDXX), Qiagen (QGEN) and InnovAge Holding (INNV) - The Globe and Mail
CT Prescription Buyers Could See Refunds In $17.9M Drug Price-Fixing Settlement - AOL.com
Quarterly Earnings: Is HGBL in a long term uptrendTrade Risk Summary & Real-Time Market Trend Scan - baoquankhu1.vn
Connecticut AG William Tong settles with Lannett and Bausch for nearly $18 million - fox61.com
Michigan AG Secures $17.85M in Settlements with Lannett, Bausch Over Generic Drug Price-Fixing Allegations - Hoodline
Nebraska Attorney General’s Office Announces Settlements with Lannett and Bausch Totaling $17.85 Million Over Conspiracies to Inflate Prices and Limit Competition - chadronradio.com
Maryland Announces $17.85 Million Settlement in Drug Pricing Case - The MoCo Show -
Maryland Attorney General announces $17.85 million settlements with generic drug manufacturers - nottinghammd.com
Analyst Downgrade: Is now the right time to enter ADNT2025 Bull vs Bear & Weekly High Return Forecasts - baoquankhu1.vn
Overlooked and Undervalued: Why Bausch Health Companies Deserves Attention - Finviz
Bausch Health Companies Inc. (BHC): Investor Outlook With A 28.97% Potential Upside - DirectorsTalk Interviews
AG Jennings Secures $17.85-million Settlement with Lannett and Bausch; Compensation Possible - WGMD
Attorney General Jeff Jackson Reaches $17.85 Million Settlement with Lannett and Bausch Over Generic Drug Price Fixing; Sues Novartis and Sandoz - NCDOJ (.gov)
How to get compensation after DC, Md. and Va. settle $17.85M drug price fixing lawsuit - WJLA
South Dakota settles with two generic drug companies; Joins lawsuit against a third - DRGNews
Attorneys general across the U.S, including Illinois, reach nearly $18 million drug settlement - cbsnews.com
Lannett and Bausch reach $18M drug price-fixing settlement with states - Crain's New York Business
Colorado and coalition strike a deal with drug companies accused of price-fixing - Colorado Public Radio
Arizona AG announces settlements over generic drug prices - KTAR News 92.3 FM
South Dakota joins settlements totaling $17.85 million over generic drug price fixing - KOTA Territory News
AG Sunday Announces $17.85M National Settlement Over Generic Drug Price-Fixing; Pennsylvanians are Eligible for Compensation - attorneygeneral.gov
Lannett and Bausch Drug Price Fixing Deal Reaches $17.85M Multistate Settlement - USA Herald
South Dakota Attorney General Jackley Announces Settlement With Two Generic Drug Companies - South Dakota State News (.gov)
Bausch, Lannett To Pay $17.9M In Drug Price-Fixing Deal - Law360
Attorney General Tong Announces Settlements With Lannett and Bausch - CT.GOV-Connecticut's Official State Website (.gov)
Has The Market Gone Too Far In Marking Down Bausch Health (BHC) Shares? - Yahoo Finance
Bausch Health Trial Miss Puts Liver Program And Valuation In Focus - Yahoo Finance
Phase 3 RED-C Miss for Hepatic Encephalopathy Prevention Might Change The Case For Investing In Bausch Health Companies (BHC) - simplywall.st
Institutional Investors May Adopt Severe Steps After Bausch Health Companies Inc.'s (NYSE:BHC) Latest 15% Drop Adds to a Year Losses - 富途牛牛
Earnings Beat: How do insiders feel about Central Plains Bancshares IncPortfolio Performance Summary & Growth Focused Entry Reports - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Tonix Pharma (TNXP), Revolution Medicines (RVMD) and Bausch Health Companies (BHC) - The Globe and Mail
Bausch Health Companies Inc. (BHC) Stock Analysis: Exploring A 28% Potential Upside - DirectorsTalk Interviews
Does Bausch Health Companies Inc. have a sustainable dividend2025 Pullback Review & Weekly Top Performers Watchlists - mfd.ru
Can Bausch Health Companies Inc. expand into new marketsJuly 2025 Trends & Smart Money Movement Tracker - mfd.ru
Myopia And Presbyopia Treatment Market Is Going to Boom | ALCON - openPR.com
Trend Recap: Can Bausch Health Companies Inc sustain its profitabilityIndex Update & Weekly Breakout Watchlists - baoquankhu1.vn
Portfolio Shifts: What drives Bausch Health Companies Incs stock priceGap Up & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Bausch Health stock unchanged as Phase 3 RED-C trial fails primary endpoint - Investing.com Nigeria
Down 17.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Bausch (BHC) - Finviz
Bausch Health’s new formulation of Xifaxan fails pair of Phase III trials - Yahoo Finance
Bausch Health's brain dysfunction treatment fails late-stage trials - Reuters
Nasdaq Moves: Can Bausch Health Companies Inc beat the S P 5002025 Trade Ideas & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
1.21%
0.15%
자본화:
|
볼륨(24시간):